Safety and Immunogenicity of SARS-CoV-2 Vaccines in Patients With Chronic Liver Diseases (CHESS-NMCID 2101): A Multicenter Study.

Abstract

BACKGROUND & AIMS:

We aimed to assess the safety and immunogenicity of inactivated whole-virion severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in patients with chronic liver diseases (CLD) in this study.

METHODS:

This was a prospective, multi-center, open-label study. Participants aged over 18 years with confirmed CLD and healthy volunteers were enrolled. All participants received 2 doses of inactivated whole-virion SARS-CoV-2 vaccines. Adverse reactions were recorded within 14 days after any dose of SARS-CoV-2 vaccine, laboratory testing results were collected after the second dose, and serum samples of enrolled subjects were collected and tested for SARS-CoV-2 neutralizing antibodies at least 14 days after the second dose.

RESULTS:

A total of 581 participants (437 patients with CLD and 144 healthy volunteers) were enrolled from 15 sites in China. Most adverse reactions were mild and transient, and injection site pain (n = 36; 8.2%) was the most frequently reported adverse event. Three participants had grade 3 aminopherase elevation (defined as alanine aminopherase >5 upper limits of normal) after the second dose of inactivated whole-virion SARS-CoV-2 vaccination, and only 1 of them was judged as severe adverse event potentially related to SARS-CoV-2 vaccination. The positive rates of SARS-CoV-2 neutralizing antibodies were 76.8% in the noncirrhotic CLD group, 78.9% in the compensated cirrhotic group, 76.7% in the decompensated cirrhotic group (P = .894 among CLD subgroups), and 90.3% in healthy controls (P = .008 vs CLD group).

CONCLUSION:

Inactivated whole-virion SARS-CoV-2 vaccines are safe in patients with CLD. Patients with CLD had lower immunologic response to SARS-CoV-2 vaccines than healthy population. The immunogenicity is similarly low in noncirrhotic CLD, compensated cirrhosis, and decompensated cirrhosis.

• Authors: Jingwen Ai, Jitao Wang, Dengxiang Liu, Huiling Xiang, Ying Guo, Jiaojian Lv, Qiran Zhang, Jinlong Li, Xiaochong Zhang, Qianqian Li, Jing Liang, Xiaoqing Guo, Yinong Feng, Luxiang Liu, Xuying Zhang, Wei Qin, Xiaodong Wang, Wei Rao, Qun Zhang, Qiuju Tian, Yanliang Zhang, Faren Xie, Shujun Jiang, Yan Yan, Yuanwang Qiu, Hangyuan Wu, Zhiyun Hou, Nina Zhang, Aiguo Zhang, Jiansong Ji, Jie Yang, Jiansheng Huang, Zhongwei Zhao, Ye Gu, Li Bian, Zhen Zhang, Shengqiang Zou, Hailei Ji, Guohong Ge, Xiufang Du, Aifang Hou, Ying Zhu, Qingwei Cong, Juan Xu, Hongmei Zu, Yun Wang, Zhaolan Yan, Xiaosong Yan, Yangzhen BianBa, Qu Ci, Liting Zhang, Shiying Yang, Xiaoqin Gao, Li Zhong, Song He, Chuan Liu, Yifei Huang, Yanna Liu, Dan Xu, Qingliang Zhu, Xinxin Xu, Muhan Lv, Wenhong Zhang, Xiaolong Qi
• Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association (Clin Gastroenterol Hepatol) Vol. 20 Issue 7 Pg. 1516-1524.e2 (07 2022) ISSN: 1542-7714 [Electronic] United States
• PMID: 34942370 (Publication Type: Journal Article, Multicenter Study)
• Copyright: Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.

Chemical References

• Antibodies, Neutralizing
• Antibodies, Viral
• COVID-19 Vaccines

Topics

• Adult
• Antibodies, Neutralizing
• Antibodies, Viral
• COVID-19 (prevention & control)
• COVID-19 Vaccines (adverse effects, immunology)
• Double-Blind Method
• Humans
• Immunogenicity, Vaccine
• Liver Cirrhosis (complications)
• Liver Diseases (complications)
• Prospective Studies
• SARS-CoV-2